Vimarsana
Biggest News Aggregation in the World

Page 25 - Equity Capital Changes News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Equity Capital Changes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Equity Capital Changes Today - Breaking & Trending Today

UPDATE 2-THG sees no reason for share slump as volatility continues - Vimarsana News

UPDATE 2-THG sees no reason for share slump as volatility continues

* Shares dropped 35% on Tuesday, short-seller benefitted (Adds background, analyst quote, updates share price)

UPDATE 1-GIC-backed clinical trial firm WCG withdraws U.S. IPO plans - Vimarsana News

UPDATE 1-GIC-backed clinical trial firm WCG withdraws U.S. IPO plans

WCG Clinical Inc, a clinical trial solutions company backed by Singapore's sovereign wealth fund GIC, on Wednesday filed to withdraw its initial public offering, joining a list of companies that pulled the plug on their offerings in recent weeks.

Mastercard-backed AvidXchange valued at $4.6 billion in tepid Nasdaq debut - Vimarsana News

Mastercard-backed AvidXchange valued at $4.6 billion in tepid Nasdaq debut

Business payments firm AvidXchange Inc hit a market capitalization of roughly $4.62 billion on Wednesday in a lukewarm market debut, mirroring investor concerns of growing volatility in the U.S. capital market.

Indian shares end higher on auto boost, vaccine cheer; inflation in focus - Vimarsana News

Indian shares end higher on auto boost, vaccine cheer; inflation in focus

Indian shares closed higher on Tuesday, boosted by automobile stocks and an emergency-use nod for Bharat Biotech's COVID-19 shot in kids, with investors awaiting the country's retail inflation data due later in the day.

GSK on track with consumer split as buyout report boosts shares - Vimarsana News

GSK on track with consumer split as buyout report boosts shares

GlaxoSmithKline is "firmly on track" to spin off its consumer health business next year, the British drugmaker said on Tuesday, after Bloomberg News reported the unit could attract bids from private equity firms such as Advent, CVC and KKR.